Azithromycin

AWaRe
C. diff Risk

Medium

Oral Bioavailability

Excellent

Approximate Cost

IV:$
PO:$

Spectrum Of Activity

Dosing

Respiratory infection - 500mg PO/IV on day 1 then 250mg daily for 4 days

Non-respiratory infection - 500 mg PO/IV daily

Infants > 3 months10 mg/kg/dose on Day 1 (max 500mg/dose) followed by 5 mg/kg/dose (max 250mg/dose) on Days 2-5

Infants > 3 months10 mg/kg/dose-IV/PO Daily (Max dose: 500 mg/dose)

General Information

  • GI effects

  • Cholestatic jaundice

  • QT prolongation

  • Allergic reaction

Laboratory

  • Consider periodic LFTs with prolonged use

Clinical

  • Hypersensitivity

  • GI effects

  • Drug interactions

  • QT prolongation with risk factors

  • Other drugs that prolong QTc

  • ¬†Increases cyclosporine levels

  • May increase digoxin levels

  • Statins increased risk of rhabdomyolysis

Very high tissue penetration and concentration intracellularly means in vivo activity may not be predicted by in vitro testing - i.e. Salmonella spp

Antimicrobial class: Macrolide

Pregnancy category: B

Average serum half life: 68 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor

  • Community acquired pneumonia

  • Pertussis

  • Upper respiratory tract infections

  • ¬†Chlamidial infections

  • Mycobacterial infections,

  • ¬†Mycobacterium avium complex (MAC) prophylaxis in HIV patients